Previous close | 153.48 |
Open | 150.16 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 149.24 - 151.00 |
52-week range | 118.16 - 153.88 |
Volume | |
Avg. volume | 4,396 |
Market cap | 236.273B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 36.94 |
EPS (TTM) | 4.04 |
Earnings date | 25 Jul 2024 |
Forward dividend & yield | 2.86 (1.92%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).